Exalenz reports trial success for breath test bacteria detector

The company aims to obtain FDA approval for its device.

Exalenz Bioscience (TASE: EXEN), which develops and sells instruments for diagnosing diseases of the digestive system through breath tests, announced a further clinical trial success today. The trial was conducted with the aim of obtaining US Food and Drug Administration (FDA) approval for use of the company's IRMS device and its examination kit for identifying Helicobacter pylori bacteria.

Exalenz, among whose shareholders are Moshe (Mori) Arkin and Hadasit, the technology transfer company of Hadassah Hospital, carried out the trial among 167 patients, and obtained a 99.2% degree of accuracy in the results.

Exalenz CEO Steven Eitan said, "The trial results and its impressive success represent an important milestone in the company's business strategy. In addition, the results and the use of the new model considerably enlarge the company's potential market of H. pylori examinations. We believe that a market segment has opened up for us of tests in central laboratories that the company intends to set up. We believe that revenue from this sales model will amount to millions of dollars in 2010."

Published by Globes [online], Israel business news - www.globes-online.com - on December 13, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס